Pediatric patients antiretrovirals

HIV infection The safety and effectiveness of twice-daily lamivudine in combination with other antiretroviral agents have been established in pediatric patients 3 months of age and older. 

Pancreatitis Pancreatitis has been observed in antiretroviral nucleoside-experienced pediatric patients receiving lamivudine. Use lamivudine with caution in pediatric patients with a history of prior antiretroviral nucleoside exposure, a history of pancreatitis, or other significant risk factors for the development of pancreatitis. Stop lamivudine treatment immediately if clinical signs, symptoms, or lab abnormalities suggestive of pancreatitis occur (see Adverse Reactions). 

---